ImmuPharma plc (LON:IMM – Get Free Report) was down 7.8% during mid-day trading on Wednesday . The company traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.67 ($0.03). Approximately 2,364,745 shares changed hands during trading, a decline of 79% from the average daily volume of 11,474,686 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Price Performance
The firm’s fifty day simple moving average is GBX 3.92 and its 200 day simple moving average is GBX 2.48. The company has a market capitalization of £11.35 million, a PE ratio of -4.62 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- What is the Australian Securities Exchange (ASX)
- Will 2025 Be the Year the Energy Sector Finally Breaks Out?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- NextEra Energy Stock Sees Spike in Bullish Call Activity
- Investing in Construction Stocks
- Top 3 Stocks Mega Investors Are Buying Now
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
